These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 33131062

  • 1. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
    Banini BA, Kumar DP, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, Wang L, Guan HP, Oseini AM, Alonso C, Bedossa P, Koduru SV, Min HK, Sanyal AJ.
    Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
    [Abstract] [Full Text] [Related]

  • 2. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D, Ahnmark A, Pingitore P, Ciociola E, Ahlstedt I, Andréasson AC, Sasidharan K, Madeyski-Bengtson K, Zurek M, Mancina RM, Lindblom A, Bjursell M, Böttcher G, Ståhlman M, Bohlooly-Y M, Haynes WG, Carlsson B, Graham M, Lee R, Murray S, Valenti L, Bhanot S, Åkerblad P, Romeo S.
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [Abstract] [Full Text] [Related]

  • 3. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ, Xin YN, Geng N, Jiang M, Zhang DD, Xuan SY.
    World J Gastroenterol; 2015 Jan 21; 21(3):794-802. PubMed ID: 25624712
    [Abstract] [Full Text] [Related]

  • 4. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
    Su H, Haque M, Becker S, Edlund K, Duda J, Wang Q, Reißing J, Marschall HU, Candels LS, Mohamed M, Sjöland W, Liao L, Drexler SA, Strowig T, Rahnenführer J, Hengstler JG, Hatting M, Trautwein C.
    Liver Int; 2023 Aug 21; 43(8):1699-1713. PubMed ID: 37073116
    [Abstract] [Full Text] [Related]

  • 5. PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.
    Rady B, Nishio T, Dhar D, Liu X, Erion M, Kisseleva T, Brenner DA, Pocai A.
    PLoS One; 2021 Aug 21; 16(12):e0260721. PubMed ID: 34879108
    [Abstract] [Full Text] [Related]

  • 6. Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells.
    Hao L, Ito K, Huang KH, Sae-tan S, Lambert JD, Ross AC.
    Metabolism; 2014 Oct 21; 63(10):1352-62. PubMed ID: 25060692
    [Abstract] [Full Text] [Related]

  • 7. PNPLA3 I148M polymorphism and progressive liver disease.
    Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L.
    World J Gastroenterol; 2013 Nov 07; 19(41):6969-78. PubMed ID: 24222941
    [Abstract] [Full Text] [Related]

  • 8. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.
    Bruschi FV, Claudel T, Tardelli M, Caligiuri A, Stulnig TM, Marra F, Trauner M.
    Hepatology; 2017 Jun 07; 65(6):1875-1890. PubMed ID: 28073161
    [Abstract] [Full Text] [Related]

  • 9. Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
    Murray JK, Long J, Liu L, Singh S, Pruitt D, Ollmann M, Swearingen E, Hardy M, Homann O, Wu B, Holder JR, Sham K, Herberich B, Lo MC, Dou H, Shkumatov A, Florio M, Rulifson IC.
    Nucleic Acid Ther; 2021 Oct 07; 31(5):324-340. PubMed ID: 34297902
    [Abstract] [Full Text] [Related]

  • 10. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
    Caon E, Martins M, Hodgetts H, Blanken L, Vilia MG, Levi A, Thanapirom K, Al-Akkad W, Abu-Hanna J, Baselli G, Hall AR, Luong TV, Taanman JW, Vacca M, Valenti L, Romeo S, Mazza G, Pinzani M, Rombouts K.
    J Hepatol; 2024 Jun 07; 80(6):941-956. PubMed ID: 38365182
    [Abstract] [Full Text] [Related]

  • 11. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, Bedossa P, Sanyal AJ.
    Sci Rep; 2020 Jun 09; 10(1):9330. PubMed ID: 32518275
    [Abstract] [Full Text] [Related]

  • 12. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH.
    Bruschi FV, Tardelli M, Herac M, Claudel T, Trauner M.
    Liver Int; 2020 May 09; 40(5):1098-1110. PubMed ID: 32043752
    [Abstract] [Full Text] [Related]

  • 13. AQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M.
    Tardelli M, Bruschi FV, Claudel T, Moreno-Viedma V, Halilbasic E, Marra F, Herac M, Stulnig TM, Trauner M.
    Sci Rep; 2017 Nov 07; 7(1):14661. PubMed ID: 29116096
    [Abstract] [Full Text] [Related]

  • 14. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Unalp-Arida A, Ruhl CE.
    Hepatology; 2020 Mar 07; 71(3):820-834. PubMed ID: 31705824
    [Abstract] [Full Text] [Related]

  • 15. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.
    Valenti L, Maggioni P, Piperno A, Rametta R, Pelucchi S, Mariani R, Dongiovanni P, Fracanzani AL, Fargion S.
    World J Gastroenterol; 2012 Jun 14; 18(22):2813-20. PubMed ID: 22719190
    [Abstract] [Full Text] [Related]

  • 16. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
    Park J, Zhao Y, Zhang F, Zhang S, Kwong AC, Zhang Y, Hoffmann HH, Bushweller L, Wu X, Ashbrook AW, Stefanovic B, Chen S, Branch AD, Mason CE, Jung JU, Rice CM, Wu X.
    J Hepatol; 2023 Jan 14; 78(1):45-56. PubMed ID: 36049612
    [Abstract] [Full Text] [Related]

  • 17. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L.
    Hepatology; 2016 Mar 14; 63(3):787-98. PubMed ID: 26605757
    [Abstract] [Full Text] [Related]

  • 18. The PNPLA3 variant I148M reveals protective effects toward hepatocellular carcinoma in mice via restoration of omega-3 polyunsaturated fats.
    Patsenker E, Thangapandi VR, Knittelfelder O, Palladini A, Hefti M, Beil-Wagner J, Rogler G, Buch T, Shevchenko A, Hampe J, Stickel F.
    J Nutr Biochem; 2022 Oct 14; 108():109081. PubMed ID: 35691594
    [Abstract] [Full Text] [Related]

  • 19. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
    Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro G, Magni P, Fargion S.
    BMC Gastroenterol; 2012 Aug 16; 12():111. PubMed ID: 22898488
    [Abstract] [Full Text] [Related]

  • 20. PNPLA3 I148M mediates the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells.
    Yuan S, Liu H, Yuan D, Xu J, Chen Y, Xu X, Xu F, Liang H.
    J Cell Mol Med; 2020 Jan 16; 24(2):1541-1552. PubMed ID: 31793207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.